New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
60 Degrees Pharmaceuticals, Inc.
SXTP
Shape
US Flag

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

4M

Biotechnology

Next Earning date - 13 Aug 2025

4M

Biotechnology

Next Earning date - 13 Aug 2025

2.62USD

Shape0.01 ( 0.38%)
Market Open
favorite-chart

Relative Strenght

82
favorite-chart

Volume Buzz

-87%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

93%
OverviewChart

Quote Panel

Shape
Updated July 11, 2025
1W 12.45 % 1M 14.91 % 3M -19.63 % 1Y -82.21 %

Key Metrics

Shape

  • Market Cap

    3.86M

  • Shares Outstanding

    1.47M

  • Share in Float

    1.37M

  • Dividende

    0

  • Earning Date

    13 Aug 2025

  • Price Target

    2.62

  • Average Volume

    197926

  • Beta

    -0.8776657

  • Range

    1.41-36

  • Industry

    Biotechnology

  • Website

    https://60degreespharma.com

  • Sector

    Healthcare

Fundamentals

Shape

N/A

P/E Ratio

5.87x

P/S Ratio

0.81x

P/B Ratio

0.0

Debt/Equity

-1564.6%

Net Margin

$-21.9

EPS

How SXTP compares to sector?

P/E Ratio

SXTP

0x

Relative Strength

Shape

SXTP

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$2M

Shape1349%

2026-Revenue

$3.04

Shape-95%

2026-EPS

$2M

Shape-0%

2026-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Shape

Buy

Price Target

NaN(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

No Data Available

Earnings GrowthShape

status-upYoY

Current

Estimates

Q2.23

arrow
arrow

N/A

-1.40
vs -0.39

Q3.23

arrow
arrow

N/A

-18.01
vs -0.26

Q4.23

arrow
arrow

N/A

-0.34
vs -0.35

Q1.24

arrow
arrow

N/A

-26.41
vs -0.47

Q2.24

arrow
arrow

N/A

-21.15
vs -1.40

Q3.24

arrow
arrow

N/A

-4.65
vs -18.01

Q4.24

arrow
arrow

N/A

-14.20
vs -0.34

Q1.25

arrow
arrow

N/A

-1.56
vs -26.41

Q2.25

arrow
arrow

N/A

-0.96
vs -21.15

Q3.25

arrow
arrow

N/A

-0.83
vs -4.65

Sales GrowthShape

status-upYoY

Current

Estimates

Q2.23

arrow
arrow

+32%

59.5K  vs 45.2K

Q3.23

arrow
arrow

-70%

51.2K  vs 168.2K

Q4.23

arrow
arrow

+156%

42.7K  vs -75652

Q1.24

arrow
arrow

+751%

146.1K  vs 17.2K

Q2.24

arrow
arrow

+111%

125.7K  vs 59.5K

Q3.24

arrow
arrow

+164%

135.3K  vs 51.2K

Q4.24

arrow
arrow

+441%

230.8K  vs 42.7K

Q1.25

arrow
arrow

+12%

163.6K  vs 146.1K

Q2.25

arrow
arrow

+226%

410K  vs 125.7K

Q3.25

arrow
arrow

+225%

440K  vs 135.3K

Return on EquityShape

status-upQoQ

Q2.23

arrow
arrow

+15%

0.15
vs 0.14

Q3.23

arrow
arrow

+64%

0.64
vs 0.15

Q4.23

arrow
arrow

-41%

-0.41
vs 0.64

Q1.24

arrow
arrow

+6%

0.06
vs -0.41

Q2.24

arrow
arrow

-137%

-1.37
vs 0.06

Q3.24

arrow
arrow

-36%

-0.36
vs -1.37

Q4.24

arrow
arrow

-51%

-0.51
vs -0.36

Q1.25

arrow
arrow

-46%

-0.46
vs -0.51

Institutionnal OwnershipShape

status-up

Earnings Growth

Latest News

SXTP

globenewswire.com

8 hours ago

60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format
SXTP

globenewswire.com

8 hours ago

Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals
SXTP

globenewswire.com

8 hours ago

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey
SXTP

globenewswire.com

8 hours ago

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21
SXTP

globenewswire.com

8 hours ago

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health
SXTP

globenewswire.com

16 hours ago

60 Degrees Pharmaceuticals Announces First Quarter 2025 Results